News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Guidance
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Sirenia Capital Management LP and Alex Silverstein have disclosed a beneficial ownership of 8,911,348 ordinary shares in InflaRx N.V. (IFRX), representing a 6.1% stake in the company. This disclosure was made via a Schedule 13G filing. The shares are held by investment funds managed …
InflaRx N.V. (NASDAQ: IFRX) announced an SEC filing regarding the effectiveness of an F-3 form. This "Notice of Effectiveness" from the SEC confirms that the company's shelf registration, filed under Form F-3, became effective on August 12, 2026, at 4:30 P.M. The filing indicates …
InflaRx (NASDAQ:IFRX) reported a quarterly loss of $0.11 per share, missing the consensus estimate by $0.04. Despite the earnings miss, the stock rose $0.12 to $1.84, with a market capitalization of approximately $133 million. Analysts maintain a "Moderate Buy" rating with an average price …
InflaRx NV has reported its earnings for the quarter that ended on June 30. This summary provides key financial information from the company's performance during that period. The full article containing detailed results is available for subscribers.
InflaRx N.V. (Nasdaq: IFRX) recently raised $140 million through an underwritten offering, boosting its total funds to €158.4 million and extending its cash runway into 2029. The company reported a narrowed H1 net loss of €16.2 million and is focusing its pipeline on izicopan …
FMR LLC and Abigail P. Johnson have reported a 5.5% beneficial ownership stake in Inflarx N.V. (IFRX) through a Schedule 13G filing. This amounts to 8,163,341 shares, with FMR LLC holding sole voting and dispositive power over all shares, while Abigail P. Johnson has …
InflaRx N.V. (IFRX) has filed a Form F-3 shelf registration to offer up to $250 million in mixed securities, including ordinary shares, debt securities, and warrants, to be issued periodically. The biopharmaceutical company, which focuses on anti-C5a/C5aR inflammatory therapies, stated that the proceeds from …
InflaRx N.V. (IFRX) is making significant progress with its advanced pipeline in AAV and renal diseases, supported by strong financial reserves and a successful public offering. The company has reduced its expenses and net loss year-over-year and projects a cash runway extending through 2029, …
InflaRx N.V. reported its Q2 2026 financial results and provided a business update, highlighting significant progress in developing izicopan, an oral C5a receptor inhibitor, for ANCA-associated vasculitis (AAV) and other renal diseases. The company announced €158.4 million in cash and equivalents, projected to fund …
Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as plannedInitiated feasibility assessment for broadened strategy for AAV in Europe Reported new pre-clinical data supporting the safety and differentiation of izicopan as a next-generation oral inhibitor of C5aRPharmacokinetic …
InflaRx N.V. (NASDAQ:IFRX) generated 0.00 USD in total revenue last year. Its top-performing segment was Novel Therapeutic Products, contributing 33.10K USD, down from 179.33K USD the previous year. The United States was the largest geographical contributor, matching the performance of the top segment.
InflaRx N.V. (Nasdaq: IFRX) announced that it will report its second-quarter 2026 financial and operating results on August 6, 2026, before the market opens. The company pioneers anti-inflammatory therapeutics and will not be hosting a conference call.
InflaRx (Nasdaq: IFRX) is scheduled to report its second-quarter 2026 financial and operating results on August 6, 2026, before the U.S. market opens. The biopharmaceutical company has announced that it does not plan to hold a conference call in conjunction with this release. InflaRx …
This article provides a valuation analysis of InflaRx NV (IFRX), noting its current valuation score of 6.64. The company ranks 296 out of 385 in the Biotechnology & Medical Research industry. It also highlights InflaRx NV's P/E ratio, while noting that relevant P/B, P/S, …
InflaRx N.V. reported total revenue of 0.00 EUR last year, with its top-performing segment, Novel Therapeutic Products, contributing 28.18K EUR. The United States was the primary regional contributor, accounting for 28.18K EUR of the company's revenue. This marks a significant decrease from the previous …
This page on TradingKey provides a detailed quarterly and annual income statement for InflaRx NV (IFRX), including a breakdown of revenues, expenses, and net income over numerous fiscal periods. It also features frequently asked questions to help users understand how to interpret the financial …
InflaRx N.V. (IFRX) generated no revenue last year, with its top-performing segment, Novel Therapeutic Products, contributing $33.10K, down from $179.33K the previous year. The United States was the primary regional contributor to this revenue. The company's financials are detailed on TradingView, showing a significant …
InflaRx NV (IFRX) closed at $1.740, up 0.58%, with a high institutional ownership. The company, focused on developing monoclonal antibodies for inflammatory diseases, is in a growing phase with strong fundamentals despite recent stock market performance. Analysts rate IFRX a "Buy" with a target …
This article from TradingKey provides an overview of institutional confidence in InflaRx NV (IFRX). It details the shareholdings and activity of several institutional investors, including significant changes in holdings. The data was updated on July 24, 2026, showing a consistent institutional confidence score.
This article provides a technical analysis of InflaRx NV (IFRX), detailing its current stock price, market cap, and price momentum score. It evaluates the stock using various technical indicators like MACD, RSI, and moving averages, providing signals for buying, selling, or neutrality. The analysis …
Search by ticker symbol or company name and select a result to open its chart.